Mabpharm Limited (2181.HK)

HKD 0.5

(0.0%)

Operating Income Summary of Mabpharm Limited

Mabpharm Limited's latest annual operating income in 2023 was -201.98 Million CNY , up 2.03% from previous year.
Mabpharm Limited's latest quarterly operating income in 2024 Q2 was -46.47 Million CNY , down 0.0% from previous quarter.
Mabpharm Limited reported an annual operating income of -203.83 Million CNY in 2022, up 29.54% from previous year.
Mabpharm Limited reported an annual operating income of -289.26 Million CNY in 2021, down -60.09% from previous year.
Mabpharm Limited reported a quarterly operating income of -46.47 Million CNY for 2024 Q1, up 11.85% from previous quarter.
Mabpharm Limited reported a quarterly operating income of -48.27 Million CNY for 2023 Q2, down 0.0% from previous quarter.

Annual Operating Income Chart of Mabpharm Limited (2023 - 2017)

Historical Annual Operating Income of Mabpharm Limited (2023 - 2017)

Year	Operating Income	Operating Income Growth
2023	-201.98 Million CNY	2.03%
2022	-203.83 Million CNY	29.54%
2021	-289.26 Million CNY	-60.09%
2020	-180.69 Million CNY	7.26%
2019	-194.83 Million CNY	-31.55%
2018	-148.11 Million CNY	-233.75%
2017	-44.37 Million CNY	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	-46.47 Million CNY	0.0%
2024 Q1	-46.47 Million CNY	11.85%
2023 Q2	-48.27 Million CNY	0.0%
2023 Q1	-48.27 Million CNY	6.23%
2023 FY	-199.69 Million CNY	2.03%
2023 Q4	-52.72 Million CNY	0.0%
2023 Q3	-52.72 Million CNY	-9.22%
2022 Q4	-51.47 Million CNY	0.0%
2022 Q2	-61.64 Million CNY	0.0%
2022 Q1	-61.64 Million CNY	20.35%
2022 Q3	-51.47 Million CNY	16.49%
2022 FY	-203.83 Million CNY	29.54%
2021 Q4	-77.39 Million CNY	0.0%
2021 Q1	-71.36 Million CNY	-50.81%
2021 Q2	-71.36 Million CNY	0.0%
2021 Q3	-77.39 Million CNY	-8.45%
2021 FY	-289.26 Million CNY	-60.09%
2020 Q4	-47.32 Million CNY	0.0%
2020 Q3	-47.32 Million CNY	-3.36%
2020 FY	-180.69 Million CNY	7.26%
2020 Q2	-45.78 Million CNY	0.0%
2020 Q1	-45.78 Million CNY	12.08%
2019 Q1	-41.52 Million CNY	2.68%
2019 FY	-194.83 Million CNY	-31.55%
2019 Q3	-52.07 Million CNY	-25.41%
2019 Q2	-41.52 Million CNY	0.0%
2019 Q4	-52.07 Million CNY	0.0%
2018 Q2	-17.17 Million CNY	0.0%
2018 Q3	-42.66 Million CNY	-148.36%
2018 Q4	-42.66 Million CNY	0.0%
2018 Q1	-17.17 Million CNY	44.24%
2018 FY	-148.11 Million CNY	-233.75%
2017 Q1	-6.93 Million CNY	0.0%
2017 FY	-44.37 Million CNY	0.0%
2017 Q4	-30.8 Million CNY	0.0%
2017 Q2	-6.93 Million CNY	0.0%
2016 Q4	-6.93 Million CNY	0.0%

Peer Operating Income Comparison of Mabpharm Limited

Name	Operating Income	Operating Income Difference
Uni-Bio Science Group Limited	67.76 Million HKD	398.052%
CK Life Sciences Int'l., (Holdings) Inc.	897.95 Million HKD	122.494%